The following video is part of our "Motley Fool Conversations" series in which health-care editor/analyst David Williamson and technology editor/analyst Andrew Tonner discuss topics across the investing world.
In today's edition, David discusses the recent capital raise at Mannkind, which hopes to get its inhaled-insulin therapy, Afrezza, on the market. Shares plunged 35% after the news, which seemed to catch the market off guard, but management stated in their Q3 conference call that they would only be able to fund operations through Q1 2012. David argues that even after this overreaction, shares are not a bargain. Even if Afrezza is approved, there may not be as large a market as investors think. Big Pharma has struggled to sell or scrapped inhaled-insulin products, so Mannkind looks to have an uphill climb even if it gets past the FDA.